Natco Pharma launches Valsartan Sacubitril tablets in India under brand name VALSAC

Published On 2019-01-31 05:00 GMT   |   Update On 2019-01-31 05:00 GMT

Valsartan Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.


Hyderabad: Soon after diversifying its portfolio by entering into agrichemical space, the Hyderabad based Natco Pharma Limited has announced the launch of Valsartan-Sacubitril tablet, under its brand VALSAC.


NATCO has launched VALSAC in 50 mg & 100 mg strengths at an MRP of INR 45.0 and INR 55.0, per tablet, respectively.


Valsartan-Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.


Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. While Sacubitril is an antihypertensive drug used in combination with valsartan.


Also Read:EU cracks down on Valsartan- blood pressure medicine made by Mylan


The firm has recently diversified its portfolio by entering into agrichemical space and initiated work on it green-field manufacturing facilities for producing niche products in that area in Nellore District of Andhra Pradesh. The facility will manufacture both agrichemical technical and formulation products. Natco expects the facilities to be commissioned by the end of 2019 with a total capital expenditure of Rs 100 crore.


Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of Rs 3.3 million. The firm has seven manufacturing facilities spread across India with modern research laboratories. It is involved in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).



Medical Dialogues had earlier reported about the company's recent foray into the agrichemical space.


Also Read: Natco Pharma ventures into agrichemical space set up Rs 100 crore facility in AP

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News